Enterprise Europe Network

Compounds for the treatment of Leishmaniasis and other diseases caused by trypanosomes

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20201216002
Published
16/12/2020
Last update
29/12/2020
Expiration date
30/12/2021

Keywords

Partner keyword: 
Biostatistics, Epidemiology
Human vaccines
Pharmaceutical Products / Drugs
Virus, Virology/Antibiotics/Bacteriology
Therapeutic services
Anatomy, Pathology, Immunology, Physiology
EXPRESS YOUR INTEREST

Summary

Summary: 
Researchers from two Spanish Universities have developed a series of useful compounds for the treatment of Leishmaniasis and other diseases caused by parasites of the Trypanosomatidae family that represent a potential alternative to the usual treatments. The researchers are looking for partners from the pharmaceutical industry interested in licensing these patented compounds.

Description

Description: 

Leishmaniasis is an infectious and parasitic disease, classified as a “neglected tropical disease” by the WHO, which affects millions of people every year and exists mainly in developing countries. Despite its relevance and incidence, there is still no effective vaccine or effective treatment to combat it. The drugs currently used have some disadvantages such as high toxicity, difficulty in administration, generation of resistance, and high cost. The global set of these problems, also common to other diseases caused by parasites of the Trypanosomatidae family, such as Chagas disease, imply the need for the development of new, more effective treatments that represent an alternative to the usual ones.

A research group from two Spanish Universities has developed a series of useful compounds for the treatment of Leishmaniasis and other diseases caused by parasites of the Trypanosomatidae family. They have observed antiparasitic activity in a series of aromatic heterocyclic compounds, thus enabling their use as a treatment against diseases caused by protozoa of the Trypanosomatidae family, mainly Leishmaniasis, and within these, visceral Leishmaniasis, cutaneous Leishmaniasis or mucocutaneous Leishmaniasis. Compounds proposed in this invention have shown antiparasitic activity against three strains of the genus Leishmania that are the main causes of Leishmaniasis.

Moreover, according to the results of the assays carried out, these compounds have lower toxicity than the toxicity associated with the use of the reference commercial treatments.

The research group is looking for partners interested in licensing these patented compounds.

Advantages & innovations

Cooperation plus value: 
- Greater antiparasitic activity. The antiparasitic activity against the Leishmania strains tested is, in almost all of the proposed compounds, higher than said activity performed by the reference commercial treatment. - Low toxicity. Current commercial treatments to combat these diseases are highly toxic. These compounds show lower toxicity than that observed in them. - Affection of the parasite without inhibiting the human enzyme. The compounds of the invention can inhibit the parasite enzyme with an IC50 value lower than that necessary to significantly inhibit the human erythrocyte enzyme. - Possibility of industrial scaling. Due to the simplicity of the proposed synthesis method and the ease of scaling it for industrial production.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
The research group is looking for companies involved in the treatment of parasitic diseases such as leishmaniasis and / or Chagas disease, in order to reach a license agreement.

Type and size

Cooperation task: 
SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500